Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells

Respiratory Research

Gail Solomon²  Duncan F Rogers¹  David B Hill³  Helmut H Albrecht²  JeanClare Seagrave⁴ 

[1] Airway Disease, National Heart & Lung Institute, Imperial College London, London, UK;Reckitt Benckiser, Parsippany, NJ, USA;The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA;Lovelace Respiratory Research Institute, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108, USA

关键词: Respiratory infections;    Mucus rheology;    Mucolytic;    MUC5AC;    Expectorant;   

Others  :  796615
DOI  :  10.1186/1465-9921-13-98

 received in 2012-06-22, accepted in 2012-10-17,  发布年份 2012

【 摘 要 】

Background

Therapeutic intervention in the pathophysiology of airway mucus hypersecretion is clinically important. Several types of drugs are available with different possible modes of action. We examined the effects of guaifenesin (GGE), N-acetylcysteine (NAC) and ambroxol (Amb) on differentiated human airway epithelial cells stimulated with IL-13 to produce additional MUC5AC.

Methods

After IL-13 pre-treatment (3 days), the cultures were treated with GGE, NAC or Amb (10–300 μM) in the continued presence of IL-13. Cellular and secreted MUC5AC, mucociliary transport rates (MTR), mucus rheology at several time points, and the antioxidant capacity of the drugs were assessed.

Results

IL-13 increased MUC5AC content (~25%) and secretion (~2-fold) and decreased MTR, but only slightly affected the G’ (elastic) or G” (viscous) moduli of the secretions. GGE significantly inhibited MUC5AC secretion and content in the IL-13-treated cells in a concentration-dependent manner (IC₅₀s at 24 hr ~100 and 150 μM, respectively). NAC or Amb were less effective. All drugs increased MTR and decreased G’ and G” relative to IL-13 alone. Cell viability was not affected and only NAC exhibited antioxidant capacity.

Conclusions

Thus, GGE effectively reduces cellular content and secretion of MUC5AC, increases MTR, and alters mucus rheology, and may therefore be useful in treating airway mucus hypersecretion and mucostasis in airway diseases.

【 授权许可】

   
2012 Seagrave et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Rogers DF: Mucoactive agents for airway mucus hypersecretory diseases. Respir Care 2007, 52:1176-1193.
• [2]Voynow JA, Rubin BK: Mucins, Mucus, and Sputum. Chest 2009, 135:505-512.
• [3]Matsui H, Randell SH, Peretti SW, Davis CW, Boucher RC: Coordinated clearance of periciliary liquid and mucus from airway surfaces. J Clin Invest 1998, 102:1125-1131.
• [4]Fahy JV, Dickey BF: Airway mucus function and dysfunction. N Engl J Med 2010, 363:2233-2247.
• [5]Hovenberg HW, Davies JR, Carlstedt I: Different mucins are produced by the surface epithelium and the submucosa in human trachea: identification of MUC5AC as a major mucin from the goblet cells. Biochem J 1996, 318:319-324.
• [6]Wickstrom C, Davies JR, Eriksen GV, Veerman EC, Carlstedt I: MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: identification of glycoforms and C-terminal cleavage. Biochem J 1998, 334(Pt 3):685-693.
• [7]Zuhdi AM, Piazza FM, Selby DM, Letwin N, Huang L, Rose MC: Muc-5/5ac mucin messenger RNA and protein expression is a marker of goblet cell metaplasia in murine airways. Am J Respir Cell Mol Biol 2000, 22:253-260.
• [8]Seagrave J, Albrecht H, Park YS, Rubin B, Solomon G, Kim KC: Effect of guaifenesin on mucin production, rheology, and mucociliary transport in differentiated human airway epithelial cells. Exp Lung Res 2011, 37:606-614.
• [9]Fulcher LM, Gabriel S, Burns KA, Yankaskas JR, Randell SH: Well-differentiated human airway epithelial cell cultures. Methods Mol Med 2004, 107:183-206.
• [10]Atherton HC, Jones G, Danahay H: IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation. Am J Physiol Lung Cell Mol Physiol 2003, 285:L730-L739.
• [11]Malerba M, Ragnoli B: Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol 2008, 4:1119-1129.
• [12]Kettle R, Simmons J, Schindler F, Jones P, Dicker T, Dubois G, Giddings J, Van HG, Jones CE: Regulation of neuregulin 1beta1-induced MUC5AC and MUC5B expression in human airway epithelium. Am J Respir Cell Mol Biol 2010, 42:472-481.
• [13]Troost FJ, Saris WH, Haenen GR, Bast A, Brummer RJ: New method to study oxidative damage and antioxidants in the human small bowel: effects of iron application. Am J Physiol Gastrointest Liver Physiol 2003, 285:G354-G359.
• [14]Hill DB, Button B: Establishment of respiratory air-liquid interface cultures and their use in studying mucin production, secretion, and function. Methods Mol Biol 2012, 842:245-258.
• [15]Vasquez P, Xu K, Mu F, Forest MG, Hill DB: Uncertainty quantification and reduction in the dynamic moduli of biological fluids. Biorheology 2012. in press
• [16]Rubin BK: The pharmacologic approach to airway clearance: mucoactive agents. Respir Care 2002, 47:818-822.
• [17]Koyama I, Matsunaga T, Harada T, Kikuno A, Hokari S, Komoda T: Ambroxol reduces LPS toxicity mediated by induction of alkaline phosphatases in rat lung. Clin Biochem 2004, 37:688-693.
• [18]Hasegawa I, Niisato N, Iwasaki Y, Marunaka Y: Ambroxol-induced modification of ion transport in human airway Calu-3 epithelia. Biochem Biophys Res Commun 2006, 343:475-482.
• [19]Kagan L, Lavy E, Hoffman A: Effect of mode of administration on guaifenesin pharmacokinetics and expectorant action in the rat model. Pulm Pharmacol Ther 2009, 22:260-265.
• [20]Thomson ML, Pavia D, McNicol MW: A preliminary study of the effect of guaiphenesin on mucociliary clearance from the human lung. Thorax 1973, 28:742-747.
• [21]Chodosh S, Medici TC, Enslein K: Objective sputum changes associated with glyceryl guiacolate in chronic bronchial diseases. Bull Physiopathol Respir 1973, 9:452-456.
• [22]Irwin RS, Boulet LP, Cloutier MM, Fuller R, Gold PM, Hoffstein V, Ing AJ, McCool FD, O'Byrne P, Poe RH, et al.: Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. Chest 1998, 114:133S-181S.
• [23]Dicpinigaitis PV, Gayle YE: Effect of guaifenesin on cough reflex sensitivity. Chest 2003, 124:2178-2181.
• [24]Sisson JH, Yonkers AJ, Waldman RH: Effects of guaifenesin on nasal mucociliary clearance and ciliary beat frequency in healthy volunteers. Chest 1995, 107:747-751.
• [25]Holmen JM, Karlsson NG, Abdullah LH, Randell SH, Sheehan JK, Hansson GC, Davis CW: Mucins and their O-Glycans from human bronchial epithelial cell cultures. Am J Physiol Lung Cell Mol Physiol 2004, 287:L824-L834.